3rd Quarter - Report
340B HEALTH for 340B HEALTH
Firm
Client
Income
—
Expenses
$251,997
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
The 340B Drug Pricing Program; FY19 LHHS Appropriations; final 2018 and proposed 2019 Outpatient Prospective Payment System Rule; proposed and final rules regarding 340B ceiling price calculations and manufacturer civil monetary penalties; delay of 340B ceiling price database; S.2312, S.2453, H.R.4710, H.R.4392, H.R.5598, H.R.6071, H.R.6240, H.R.6273, and other legislation relevant to the 340B drug pricing program
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHRYN DIBITETTO | — |
| GREG DOGGETT | — |
| DANA LAUREN GANSMAN | — |
| SUSAN PILCH | — |
| AMANDA SELLERS SMITH | — |
| MAUREEN TESTONI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.